Agreed 100%. Leo knows what Aspire will do with th
Post# of 72447
(Total Views: 445)
Posted On: 11/09/2017 3:05:30 PM
Agreed 100%. Leo knows what Aspire will do with the shares and it's stated in the 10-Q.
"To the extent Aspire Capital purchases shares under this Purchase Agreement and subsequently sells those shares purchased, the other holders of shares of our Class A common stock may experience dilution, which may be substantial. In addition, the sale of a substantial number of shares of our Class A common stock by Aspire Capital, or anticipation of such sales, could make it more difficult for us to sell equity or equity-related securities in the future at a time and price that we might otherwise wish to effect sales."
The fact that Aspire has yet to file a Schedule 13G means they have sold at least 75% of shares acquired from IPIX. I can show the math to those interested. Aruda provided more selling last year, but we don't know how much he has sold, if any, this year until the next filing.
Investors should know where the selling pressure is coming from, instead of resign to the claim that no one is selling because longs I know aren't selling, therefore it must be naked shorts. I believe Leo knows Aspire will be history soon based on this statement in the 10-Q.
"The Company may consider other plans to fund operations including: (1) raising additional capital through debt financings or from other sources; (2) additional funding through new relationships to help fund future clinical trial costs (i.e. licensing and partnerships); (3) reducing spending on one or more research and development programs by discontinuing development; and/or (4) restructuring operations to change its overhead structure. The Company may issue securities, including shares of common stock, shares of preferred stock and stock purchase contracts through private placement transactions or registered public offerings, pursuant to its registration statement on Form S-3 filed with the SEC on September 11, 2017. The Company’s future liquidity needs, and ability to address those needs, will largely be determined by the success of its product candidates and key development and regulatory events and its decisions in the future.
The Company believes that the actions discussed above are probable of occurring and alleviating the substantial doubt raised by our historical operating results and satisfying our estimated liquidity needs twelve months from the issuance of the accompanying financial statements."
"To the extent Aspire Capital purchases shares under this Purchase Agreement and subsequently sells those shares purchased, the other holders of shares of our Class A common stock may experience dilution, which may be substantial. In addition, the sale of a substantial number of shares of our Class A common stock by Aspire Capital, or anticipation of such sales, could make it more difficult for us to sell equity or equity-related securities in the future at a time and price that we might otherwise wish to effect sales."
The fact that Aspire has yet to file a Schedule 13G means they have sold at least 75% of shares acquired from IPIX. I can show the math to those interested. Aruda provided more selling last year, but we don't know how much he has sold, if any, this year until the next filing.
Investors should know where the selling pressure is coming from, instead of resign to the claim that no one is selling because longs I know aren't selling, therefore it must be naked shorts. I believe Leo knows Aspire will be history soon based on this statement in the 10-Q.
"The Company may consider other plans to fund operations including: (1) raising additional capital through debt financings or from other sources; (2) additional funding through new relationships to help fund future clinical trial costs (i.e. licensing and partnerships); (3) reducing spending on one or more research and development programs by discontinuing development; and/or (4) restructuring operations to change its overhead structure. The Company may issue securities, including shares of common stock, shares of preferred stock and stock purchase contracts through private placement transactions or registered public offerings, pursuant to its registration statement on Form S-3 filed with the SEC on September 11, 2017. The Company’s future liquidity needs, and ability to address those needs, will largely be determined by the success of its product candidates and key development and regulatory events and its decisions in the future.
The Company believes that the actions discussed above are probable of occurring and alleviating the substantial doubt raised by our historical operating results and satisfying our estimated liquidity needs twelve months from the issuance of the accompanying financial statements."
Quote:
Sort of sticks a knife in the concept that "No one is selling so it must be "naked shorts" IMHO"
(5)
(0)Innovation Pharmaceuticals Inc (IPIX) Stock Research Links
